In a transformative shift within the biopharmaceutical manufacturing sector, Avid Bioservices, a premier biologics contract development and manufacturing organization (CDMO), has announced its agreement to be acquired by GHO Capital Partners and Ampersand Capital Partners for approximately $1.1 billion. This acquisition, valued at $12.50 per share, will take Avid Bioservices private, marking a major shift […]
Ampersand Capital Partners, a middle-market private equity firm, has acquired a majority stake in American Laboratory Products Company (ALPCO), an in vitro diagnostics company, for an undisclosed price. Established in 1990, ALPCO started off as an importer and distributor of immunoassay-based products serving the North American life science markets. Currently, the company offers its proprietary […]
Global life sciences company Thermo Fisher Scientific has agreed to acquire Massachusetts-based Brammer Bio from Ampersand Capital Partners for about $1.7 billion in cash. Brammer Bio is a viral vector contract development and manufacturing organization (CDMO) serving bipharma companies seeking to develop and commercialize gene therapies. The CDMO was formed in 2016 through the merger […]